Financing
Romark Laboratories Raises $18 Million in Institutional Financing
Published in Law and Health Weekly, January 5th, 2008
The proceeds from this financing will enable Romark to advance development of its lead compound, nitazoxanide, for the treatment of hepatitis C, and advance its next-generation thiazolide drug candidates for the treatment of hepatitis B and C and other viral diseases. Romark is currently conducting a U.S. Phase 2 trial of nitazoxanide in hepatitis C patients who have failed standard treatments, and expects to begin a U.S. Phase 2 trial in treatment naive patients in the first quarter of 2008.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
More Articles from Law and Health Weekly
- Addiction Medicine
Hazelden Establishes New Center for Public Advocacy - Adenoma
Studies from Moorfields Eye Hospital provide new data on adenoma - Adverse Drug Reactions
Scientists at University of California publish research in adverse drug reactions - American Veterinary Medical Association
AVMA Lauds Senators for Approving 2007 Farm Bill Legislation that Includes the Veterinary Workforce Grant Program - Anthony Ostlund & Baer
Anthony Ostlund & Baer Obtains $130 Million Jury Verdict for Minnesota Dental Group - Applied Psychology
Studies from T.M. Shaw and co-authors have provided new information about applied psychology - More from this issue of Law and Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
